What's Happening?
Judith L. Rapoport, a pioneering figure in child psychiatry, passed away in 2026. Her career was marked by significant contributions to understanding and treating ADHD, OCD, and childhood-onset schizophrenia. Rapoport's work at the National Institute
of Mental Health (NIMH) led to the FDA approval of clomipramine for treating OCD in children and adolescents. Her research also demonstrated that the human brain continues to grow throughout adolescence, with many neuropsychiatric disorders linked to abnormal growth trajectories. Rapoport's influence extended through her mentorship, with many of her mentees now leading academic programs worldwide.
Why It's Important?
Rapoport's work has had a lasting impact on the field of child psychiatry, providing a foundation for current and future research. Her studies on brain development and psychiatric disorders have informed clinical practices and treatment approaches, improving outcomes for countless patients. Her legacy continues through the professionals she mentored, who carry forward her commitment to advancing mental health care. Rapoport's contributions highlight the importance of research in understanding complex psychiatric conditions and developing effective treatments.
